Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders for Eyenovia, Inc. (trading symbol: EYEN), held virtually on June 16, 2022. The filing details the outcomes of shareholder votes regarding director elections, stock plan amendments, and auditor ratification. Note: The request metadata lists "HYPERION DEFI, INC.", but the filing text explicitly identifies the registrant as Eyenovia, Inc.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corporate Actions
- Stock Plan Amendment: Stockholders approved an amendment to the 2018 Omnibus Stock Incentive Plan, reserving an additional 1,500,000 shares of common stock for issuance.
- Director Elections: Six nominees were elected to serve one-year terms expiring in 2023. All nominees received majority support, though significant broker non-votes were recorded.
- Auditor Ratification: Stockholders ratified the appointment of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
Voting Results and Management Commentary
Shareholder Participation: Of 31,698,424 eligible shares, a quorum of 20,525,083 shares (approximately 64.75%) was present or represented by proxy.
Director Election Results:
| Nominee | Voted For | Withheld | Broker Non-Votes |
|---|---|---|---|
| Stephen Benjamin | 11,008,713 | 1,165,053 | 8,351,317 |
| Julia A. Haller, M.D. | 11,911,116 | 262,650 | 8,351,317 |
| Tsontcho Ianchulev, M.D., M.P.H. | 12,023,241 | 150,525 | 8,351,317 |
| Rachel Jacobson | 11,082,708 | 1,091,058 | 8,351,317 |
| Kenneth B. Lee, Jr. | 12,016,788 | 156,978 | 8,351,317 |
| Charles E. Mather IV | 11,910,051 | 263,715 | 8,351,317 |
Stock Plan Approval: 10,516,638 shares voted for, 1,377,685 against, and 279,443 abstaining.
Auditor Ratification: 20,469,369 shares voted for, 38,973 against, and 16,741 abstaining.
Investor Verification Checklist
- Verify the full text of the Amended and Restated 2018 Omnibus Stock Incentive Plan (Exhibit 10.1) to understand dilution implications of the 1.5 million share increase.
- Review the 2022 Proxy Statement (filed May 2, 2022) for detailed biographies of the newly elected directors and the rationale for the stock plan amendment.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Monitor future filings for the actual issuance of shares under the amended plan to assess impact on earnings per share.